Aurinia Pharmaceuticals Inc.
AUPH
$15.99
$0.271.72%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 77.71M | 77.11M | 73.47M | 70.01M | 62.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 77.71M | 77.11M | 73.47M | 70.01M | 62.47M |
| Cost of Revenue | 13.98M | 40.55M | 8.50M | 14.55M | 14.32M |
| Gross Profit | 63.73M | 36.57M | 64.96M | 55.46M | 48.15M |
| SG&A Expenses | 22.03M | 29.26M | 26.18M | 26.02M | 20.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 279.00K | -14.77M | 929.00K | 9.25M | 4.43M |
| Total Operating Expenses | 36.28M | 34.18M | 43.72M | 49.81M | 39.09M |
| Operating Income | 41.42M | 42.94M | 29.75M | 20.20M | 23.38M |
| Income Before Tax | 43.93M | 35.69M | 31.96M | 22.16M | 24.35M |
| Income Tax Expenses | 9.57M | -175.10M | 411.00K | 643.00K | 1.01M |
| Earnings from Continuing Operations | 34.36M | 210.79M | 31.55M | 21.51M | 23.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.36M | 210.79M | 31.55M | 21.51M | 23.34M |
| EBIT | 41.42M | 42.94M | 29.75M | 20.20M | 23.38M |
| EBITDA | 46.24M | 47.80M | 34.61M | 25.06M | 28.24M |
| EPS Basic | 0.26 | 1.60 | 0.24 | 0.16 | 0.17 |
| Normalized Basic EPS | 0.21 | 0.17 | 0.15 | 0.10 | 0.12 |
| EPS Diluted | 0.25 | 1.52 | 0.23 | 0.16 | 0.16 |
| Normalized Diluted EPS | 0.20 | 0.16 | 0.15 | 0.10 | 0.11 |
| Average Basic Shares Outstanding | 132.38M | 131.94M | 131.81M | 134.87M | 138.92M |
| Average Diluted Shares Outstanding | 137.64M | 138.16M | 136.01M | 137.53M | 143.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |